CoChat

PROTEASOME INHIBITION IN MULTIPLE MYELOMA: Therapeutic Implication

Chauhan, Dharminder, Hideshima, Teru, Anderson, Kenneth C. · 2005 · Annual Review of Pharmacology and Toxicology
Cited by 136

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

▪ Abstract Normal cellular functioning requires processing of proteins regulating cell cycle, growth, and apoptosis. The ubiquitin-proteasome pathway (UBP) modulates intracellular protein degradation. Specifically, the 26S proteasome is a multienzyme protease that degrades misfolded or redundant proteins; conversely, blockade of the proteasomal degradation pathways results in accumulation of unwanted proteins and cell death. Because cancer cells are more highly proliferative than normal cells, their rate of protein translation and degradation is also higher. This notion led to the development of proteasome inhibitors as therapeutics in cancer. The FDA recently approved the first proteasome inhibitor bortezomib (Velcade™), formerly known as PS-341, for the treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM). Ongoing studies are examining other novel proteasome inhibitors, in addition to bortezomib, for the treatment of MM and other cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1146/annurev.pharmtox.45.120403.100037

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 136

Metadata

Authors
Chauhan, D., Hideshima, T., & Anderson, K. C.
Venue
Annual Review of Pharmacology and Toxicology
Published
2005-09-22
Volume
45
Issue
1
Pages
465-476
ISSN
  • 0362-1642 (ISSN-L)
  • 1545-4304
OpenAlex
W2143938165
Cited by
136
References
5
FWCI
0.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PROTEASOME INHIBITION IN MULTIPLE MYELOMA: Therapeutic Implication. https://app.cochat.ai/papers/10.1146/annurev.pharmtox.45.120403.100037
The paper
Chauhan, D., Hideshima, T., & Anderson, K. C. (2005). PROTEASOME INHIBITION IN MULTIPLE MYELOMA: Therapeutic Implication. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev.pharmtox.45.120403.100037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.